GI, colorectal

Date 11 October 2016
Event ESMO 2016 Congress
Session Congress Highlights Session 2 – The best of the ESMO 2016 Congress
Topics Colon Cancer
Rectal Cancer
Presenter Julien Taieb
Authors J. Taieb
  • Gastroenterology And Digestive Oncology, Hopital European George Pompidou, 75015 - Paris/FR

ESMO 2016 presentations referenced in this Highlights

Results of a prospective randomised control 6 vs 12 trial: Is greater tumour downstaging observed on post treatment MRI if surgery is delayed to 12-weeks versus 6-weeks after completion of neoadjuvant chemoradiotherapy?

Adjuvant FOLFOX+ cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial

Scheduled use of CEA and CT follow-up to detect recurrence of colorectal cancer: 6-12 year results from the FACS randomised controlled trial

ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8)

POLE proofreading domain mutation defines a subset of immunogenic colorectal cancers with excellent prognosis

Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): The phase II randomized MACBETH trial by GONO

Outcome according to Left vs. Right side in the Panitumumab studies 

Outcome according to Left vs. Right side in the FOLFIRI Cetuximab and FIRE 3 study

Outcome according to Left vs. Right side in the FOLFIRI Cetuximab in CRYSTAL study

Sorafenib (Soraf) and irinotecan (Iri) combination for pretreated RAS-mutated metastatic colorectal cancer (mCRC) patients: a multicentre randomized phase II trial (NEXIRI 2-PRODIGE 27)

TERRA: a randomized, double-blind, placebo-controlled phase 3 study of TAS-102 in Asian patients with metastatic colorectal cancer

A multi-center, randomized, double-blind phase II trial of FOLFIRI + regorafenib or placebo for patients with metastatic colorectal cancer who failed one prior line of oxaliplatin-containing therapy

LUME-Colon 1: Double-blind, randomised phase III study of nintedanib (BIBF 1120) plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with refractory colorectal cancer

A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): the CCTG/AGITG CO.23 trial